Sanofi (SNY)
NASDAQ: SNY · Real-Time Price · USD
47.29
+0.28 (0.60%)
Dec 19, 2024, 10:49 AM EST - Market open
Sanofi Employees
Sanofi had 86,088 employees as of December 31, 2023. The number of employees decreased by 5,485 or -5.99% compared to the previous year.
Employees
86,088
Change (1Y)
-5,485
Growth (1Y)
-5.99%
Revenue / Employee
$627,636
Profits / Employee
$58,378
Market Cap
120.59B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 86,088 | -5,485 | -5.99% |
Dec 31, 2022 | 91,573 | -3,869 | -4.05% |
Dec 31, 2021 | 95,442 | -3,970 | -3.99% |
Dec 31, 2020 | 99,412 | -997 | -0.99% |
Dec 31, 2019 | 100,409 | -3,817 | -3.66% |
Dec 31, 2018 | 104,226 | -2,340 | -2.20% |
Dec 31, 2017 | 106,566 | -293 | -0.27% |
Dec 31, 2016 | 106,859 | -2,230 | -2.04% |
Dec 31, 2015 | 109,089 | 1,702 | 1.58% |
Dec 31, 2014 | 107,387 | -4,741 | -4.23% |
Dec 31, 2013 | 112,128 | 154 | 0.14% |
Dec 31, 2012 | 111,974 | -1,745 | -1.53% |
Dec 31, 2011 | 113,719 | 12,144 | 11.96% |
Dec 31, 2010 | 101,575 | -3,292 | -3.14% |
Dec 31, 2009 | 104,867 | 6,654 | 6.78% |
Dec 31, 2008 | 98,213 | -1,282 | -1.29% |
Dec 31, 2007 | 99,495 | -794 | -0.79% |
Dec 31, 2006 | 100,289 | 3,108 | 3.20% |
Dec 31, 2005 | 97,181 | 742 | 0.77% |
Dec 31, 2004 | 96,439 | 63,353 | 191.48% |
Dec 31, 2003 | 33,086 | 650 | 2.00% |
Dec 31, 2002 | 32,436 | 1,922 | 6.30% |
Dec 31, 2001 | 30,514 | 1,314 | 4.50% |
Dec 31, 2000 | 29,200 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Elevance Health | 104,900 |
Medtronic | 95,000 |
Pfizer | 88,000 |
Boston Scientific | 48,000 |
Bristol-Myers Squibb Company | 34,100 |
Amgen | 26,700 |
Stryker | 26,700 |
Gilead Sciences | 18,000 |
SNY News
- 1 day ago - Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn's - Investopedia
- 1 day ago - Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment - WSJ
- 2 days ago - Why Are Teva And Sanofi Stocks Trading Higher On Tuesday? - Benzinga
- 2 days ago - BrightInsight Expands Global Digital Partnership with Sanofi to Build Drug Companion Apps for its Major Specialty Therapies - GlobeNewsWire
- 2 days ago - Teva, Sanofi say drug to treat IBD met primary targets - Reuters
- 2 days ago - Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn's disease - GlobeNewsWire
- 6 days ago - Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis - GlobeNewsWire
- 6 days ago - Gilead appoints Sanofi official Dietmar Berger as next chief medical officer - Reuters